Abbott Laboratories (NYSE:ABT – Get Free Report) had its price objective lifted by stock analysts at Robert W. Baird from $121.00 to $123.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the healthcare product maker’s stock. Robert W. Baird’s price objective would indicate a potential upside of 22.28% from the company’s previous close.
Several other research analysts have also weighed in on ABT. UBS Group reduced their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $119.00 to $127.00 in a report on Friday, October 2nd. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. BTIG Research lifted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Finally, TD Cowen restated a “buy” rating and set a $135.00 price objective on shares of Abbott Laboratories in a report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $118.60.
Check Out Our Latest Analysis on ABT
Abbott Laboratories Stock Down 1.8%
Shares of NYSE:ABT opened at $100.59 on Thursday. The company has a 50 day moving average price of $105.47 and a two-hundred day moving average price of $98.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a market capitalization of $174.06 billion, a PE ratio of 32.55, a PEG ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. During the same period last year, the firm posted $1.30 earnings per share. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. Analysts forecast that Abbott Laboratories will post 5.53 earnings per share for the current year.
Hedge Funds Weigh In On Abbott Laboratories
Hedge funds and other institutional investors have recently made changes to their positions in the company. Ledyard National Bank raised its holdings in shares of Abbott Laboratories by 6.4% in the 3rd quarter. Ledyard National Bank now owns 15,237 shares of the healthcare product maker’s stock valued at $1,506,000 after purchasing an additional 913 shares during the period. Culbertson A N & Co. Inc. lifted its stake in Abbott Laboratories by 0.3% in the 3rd quarter. Culbertson A N & Co. Inc. now owns 90,195 shares of the healthcare product maker’s stock valued at $8,914,000 after purchasing an additional 270 shares during the last quarter. NBT Bank N.A. bought a new position in Abbott Laboratories during the third quarter worth about $9,060,000. Root Financial Partners LLC grew its holdings in Abbott Laboratories by 93.7% during the third quarter. Root Financial Partners LLC now owns 7,430 shares of the healthcare product maker’s stock worth $734,000 after purchasing an additional 3,594 shares during the period. Finally, Precedent Wealth Partners LLC increased its position in Abbott Laboratories by 10.7% during the third quarter. Precedent Wealth Partners LLC now owns 33,354 shares of the healthcare product maker’s stock worth $3,296,000 after buying an additional 3,234 shares during the last quarter. 75.18% of the stock is owned by institutional investors.
Key Headlines Impacting Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, matching the consensus estimate, while revenue increased 14.5% year over year to $13.01 billion, slightly above the $12.99 billion forecast. Comparable sales grew 7%, and the company reaffirmed its full-year adjusted EPS guidance. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
- Positive Sentiment: Management announced a tax-free spin-off of its global Nutrition business, which includes brands such as Ensure, Similac, PediaSure, Glucerna and Pedialyte. Abbott expects the transaction to create two more focused companies, potentially accelerating Abbott’s sales growth and expanding its margin profile. Completion is targeted for the end of 2027. Abbott Nutrition Spin-Off Announcement
- Positive Sentiment: New product approvals and the European CE Mark for Abbott’s Cologuard Plus colorectal cancer test broaden the company’s diagnostics opportunity and could support longer-term growth. Abbott Secures Europe CE Mark for Colorectal Cancer Test
- Neutral Sentiment: The planned separation involves a nutrition operation generating approximately $8.5 billion in annual sales. While it may unlock value, investors will need to assess the eventual ownership structure, costs, tax implications and execution risks before determining whether the move improves shareholder returns. Abbott to Carve Out Nutrition Business
- Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing weakness in medical devices. That guidance reduction overshadowed revenue growth and the reaffirmed EPS outlook, raising concerns about near-term demand and the company’s valuation. Abbott Lowers 2026 Sales Growth Forecast
- Negative Sentiment: Although adjusted EPS met the broad consensus, it was below the $1.43 estimate tracked by Zacks. The modest earnings shortfall, combined with the lower sales outlook, contributed to the stock’s decline despite higher revenue and expanding margins. Abbott Misses Q3 Earnings Estimates
About Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.
Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.
The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- AI Spending Is Surging—But Which Stocks Still Win if It Slows Down?
- Are RTX Corporation and Northrop Grumman Ready to Break Out?
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
